Literature DB >> 15105292

RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma.

Christopher A Maxwell1, Erik Rasmussen, Fenghuang Zhan, Jonathan J Keats, Sophia Adamia, Erin Strachan, Mary Crainie, Ronald Walker, Andrew R Belch, Linda M Pilarski, Bart Barlogie, John Shaughnessy, Tony Reiman.   

Abstract

Multiple myeloma (MM) plasma cells (PCs) express receptor for hyaluronan-mediated motility (RHAMM), a hyaluronan-binding, cytoskeleton and centrosome protein. The most abundant RHAMM isoforms in MM are full-length RHAMM (RHAMMFL) and the splice variant RHAMM-exon4. We separately examined the significance of RHAMM expression, and isoform balance, in 2 groups of MM patients. In oligonucleotide microarray experiments (n=210, Arkansas), increasing RHAMM mRNA expression in MM PCs is strongly associated with osteolytic bone lesions (P <.001), and event-free (P =.05) and overall (P =.04) survival. Semiquantitative determination of RHAMM isoform expression (Alberta, Canada) used capillary electrophoretic detection and measurement of RHAMM-exon4/RHAMMFL reverse-transcriptase-polymerase chain reaction (RT-PCR) products. RHAMM isoforms are rarely expressed concurrently in single MM PCs; the pattern of isoform expression, at the single-cell level, is approximated in larger numbers of cells by the RHAMM-exon4/RHAMMFL ratio. Absolute RHAMM expression and the RHAMM-exon4/RHAMMFL ratio are only partially correlated in MM PCs; in cell lines, absolute RHAMM expression is elevated in mitosis, while RHAMM ratios remain stable. Temporal examination of MM patients' peripheral blood reveals that the RHAMM-exon4/RHAMMFL ratio increases with disease burden. The RHAMM-exon4/RHAMMFL ratio in diagnostic bone marrow samples (n=101, Alberta) is an independent prognostic factor. Thus, expression and splicing of RHAMM are important molecular determinants of disease severity in MM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105292     DOI: 10.1182/blood-2003-11-4079

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.

Authors:  Sylvia Snauwaert; Stijn Vanhee; Glenn Goetgeluk; Greet Verstichel; Yasmine Van Caeneghem; Imke Velghe; Jan Philippé; Zwi N Berneman; Jean Plum; Tom Taghon; Georges Leclercq; Kris Thielemans; Tessa Kerre; Bart Vandekerckhove
Journal:  Haematologica       Date:  2012-04-24       Impact factor: 9.941

Review 2.  Structural and regulatory roles of nonmotor spindle proteins.

Authors:  Amity L Manning; Duane A Compton
Journal:  Curr Opin Cell Biol       Date:  2008-01-04       Impact factor: 8.382

3.  Receptor for hyaluronan-mediated motility isoform B promotes liver metastasis in a mouse model of multistep tumorigenesis and a tail vein assay for metastasis.

Authors:  Yi-Chieh Nancy Du; Chen-Kung Chou; David S Klimstra; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-21       Impact factor: 11.205

4.  Targeting aurora kinases as therapy in multiple myeloma.

Authors:  Yijiang Shi; Tony Reiman; Weiqun Li; Christopher A Maxwell; Subrata Sen; Linda Pilarski; Tracy R Daniels; Manuel L Penichet; Rick Feldman; Alan Lichtenstein
Journal:  Blood       Date:  2007-01-09       Impact factor: 22.113

Review 5.  Role of receptor for hyaluronan-mediated motility (RHAMM) in human head and neck cancers.

Authors:  Hideo Shigeishi; Koichiro Higashikawa; Masaaki Takechi
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-28       Impact factor: 4.553

Review 6.  Role of Pericellular Matrix in the Regulation of Cancer Stemness.

Authors:  Sofia Avnet; Margherita Cortini
Journal:  Stem Cell Rev Rep       Date:  2016-08       Impact factor: 5.739

7.  Aberrant splice variants of HAS1 (Hyaluronan Synthase 1) multimerize with and modulate normally spliced HAS1 protein: a potential mechanism promoting human cancer.

Authors:  Anirban Ghosh; Hemalatha Kuppusamy; Linda M Pilarski
Journal:  J Biol Chem       Date:  2009-05-18       Impact factor: 5.157

Review 8.  Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells.

Authors:  Bryan P Toole; Mark G Slomiany
Journal:  Semin Cancer Biol       Date:  2008-03-26       Impact factor: 15.707

Review 9.  Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance.

Authors:  Bryan P Toole; Mark G Slomiany
Journal:  Drug Resist Updat       Date:  2008-05-19       Impact factor: 18.500

Review 10.  Centrosomes and myeloma; aneuploidy and proliferation.

Authors:  Wee J Chng; Rafael Fonseca
Journal:  Environ Mol Mutagen       Date:  2009-10       Impact factor: 3.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.